U.S. FDA Panel Blesses Otsuka’s Hyponatremia Drug
This article was originally published in PharmAsia News
Executive Summary
The fate of Otsuka Pharmaceutical's Samska may have become somewhat clearer June 25, when a U.S. FDA advisory panel voted to recommend approval of the compound for hyponatremia, or subnormal sodium in the blood